Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?

Sciascia, Savino; Coloma, Emmanuel; Radin, Massimo; Bertolaccini, Maria Laura; López-Pedrera, C.; Espinosa, Gerard; Meroni, Pier Luigi; Cervera, Ricard; Cuadrado, María J.

doi:10.1016/j.autrev.2017.09.004

Cited by 23 publications

(13 citation statements)

References 51 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, sero-positivity of all threeclassification criteria-aPLs termed the "triple positive"variant is linked with a more aggressive disease [8][9][10]. The latter may require specific therapeutic interventions such as enhanced anti-coagulations or addition of other treatment modalities [8,[11][12][13][14][15]. In contrast transient appearance of aPLs during acute thrombosis or infections may not require intervention.…”

Section: Introductionmentioning

confidence: 99%

Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome

Volkov

Seguro

Leon

et al. 2020

Autoimmun Highlights

View full text Add to dashboard Cite

Background Specific anti-phospholipids antibodies (aPLs) are used as classification criteria of the antiphospholipid syndrome (APS). These aPLs, although essential for diagnosis, do not predict disease phenotypes, which may require specific therapies. Non-criteria aPLs are rarely evaluated and their role is yet to be defined. In the current study, we aimed to examine the association between criteria and non-criteria aPLs and APS phenotypes. Methods Serum samples from 188 subjects, 130 APS patients and 58 controls were analyzed for the presence of 20 aPLs (IgG and IgM isotypes to cardiolipin (CL), beta2-glycoprotein1 (β2GP1), phosphatidic acid (P-acid), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylserine (PS), annexin-5 (AN) and prothrombin (PT) using a line immunoassay (GA Generic Assays, Germany). Sero-positivity to the different aPLs/aPLs profiles was correlated to APS phenotypes (i.e. arterial thrombosis, CNS manifestations, venous thrombosis, relapsing disease, obstetric morbidity). Results In this cohort, arterial thrombosis was associated with accumulative number of ≥ 7/20 aPLs evaluated (OR 4.1; CI 95% 1.9–96, p = 0.001) as well as the sole presence of aPT (IgG) (OR 2.3;CI 95% 1.1–5.1, p = 0.03). CNS manifestations were linked with a profile of 4 aPLs (IgG): aPT, aPG, aPI and aAN (OR 2.6;CI 95% 1.1–6.3, p = 0.03). Symptom-free period of ≥ 3 years was linked with lower number of aPLs and the presence of aPI (IgG) (OR 3.0;CI 95% 1.08–8.1, p < 0.05) or aAN (IgG) (OR 3.4;CI 95% 1.08–10.9, p < 0.05). APS related pregnancy morbidity correlated with a profile of 2 aPLs (IgG): aCL and aPS (OR 2.9; CI 95% 1.3–6.5, p < 0.05) or the sole presence of aAN (IgG) (OR 2.8; CI 95% 1.02–8, p = 0.05). Conclusion In this study, we observed an association between specific criteria/non-criteria aPLs or aPLs profiles and clinical phenotypes of APS. Our data suggest that examination of a wider variety of aPLs may allow better characterization of APS.

show abstract

Section: Introductionmentioning

confidence: 99%

Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome

Volkov

Seguro

Leon

et al. 2020

Autoimmun Highlights

View full text Add to dashboard Cite

show abstract

“…19 Besides, aPL disappearance per se cannot be considered a certain proof of no future recurrences of APS clinical manifestations since pathways independent of aPL can be engaged in the outbreak of clinical features. 7 20…”

Section: Discussionmentioning

confidence: 99%

“…8 9 Currently, a clear definition of aPL negativization is lacking and well-designed prospective studies and international consensus discussing treatment suspension in cases of persistent seroconversion are still warranted. 7…”

Section: Introductionmentioning

confidence: 99%

Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS)

et al. 2022

View full text Add to dashboard Cite

The rate of antiphospholipid antibodies (aPL) negativization in antiphospholipid syndrome (APS) patients is uncertain, but it is estimated to be as high as 8%. Currently, a consensus definition of aPL negativization is lacking, as well as international recommendations on how to approach treatment in patients with a persistent aPL negative seroconversion. Evaluate the clinical approach and level of consensus among experts from the APS Study Group of the Italian Society for Rheumatology (SIR-APS) in different clinical scenario. Experts of SIR-APS were contacted using a survey methodology. A structured survey was circulated among 30 experts.Up to 90% of the interviewed experts agreed on defining aPL negativization as the presence of two negative determinations, one year apart (90%).Almost full consensus exist among experts in some clinical settings, including: a) the role of aPL negativization in the management of a thrombotic event determined by concomitant presence of cardiovascular risk factors, both modifiable and not modifiable (90%); b) approach to young patients with triple aPL positivity who experienced pulmonary arterial thrombotic event and tested negative for aPL detection after five year of vitamin K antagonist (VKA) treatment (90%); c)the use of “extra criteria” aPL antibodies testing before pondering VKA suspension (93%). A substantial agreement exists among expert on how to define aPL negativization. VKA suspension should be embraced with extreme caution, particularly in case of previous thrombotic events and/or triple aPL positivity. Nevertheless, VKA cessation might be considered when risk factors are carefully monitored/treated and the presence for “extra criteria” is ruled out.

show abstract

“…However, the prevalence of aPL following the first unprovoked thrombotic event is 9–15% [ 14 , 15 ], and thus it is likely that many of these patients have undiagnosed APS. Following current DVT treatment guidelines in patients with undiagnosed APS leads to an inappropriate selection of DOACs instead of vitamin K antagonists (VKA) [ 16 , 17 ], and cessation of anticoagulant treatment highly increases the risk for DVT recurrence. Early diagnosis of APS is therefore mandatory for appropriate selection of anticoagulant therapy and the decision about treatment cessation.…”

Section: Introductionmentioning

confidence: 99%

The Predictive Value of the aCL and Anti-β2GPI at the Time of Acute Deep Vein Thrombosis—A Two-Year Prospective Study

et al. 2021

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is an important cause of deep vein thrombosis (DVT). According to current APS classification criteria, APS cannot be confirmed until 24 weeks after DVT. This time frame results in frequent discontinuation of anticoagulant treatment before APS is diagnosed. Therefore, the aim of our study was to evaluate the potential predictive value of anticardiolipin (aCL) and anti-β2glycoprotein I (anti-β2GPI) before discontinuation of anticoagulation therapy. Patients with newly diagnosed DVT were included into a 24-month prospective study. All patients received anticoagulant therapy. aCL and anti-β2GPI were determined at inclusion and every four weeks for the first 24 weeks and then one and two years after inclusion. APS was confirmed in 24/221 (10.9%) patients. At the time of acute DVT 20/24 (83.3%), APS patients had positive aCL and/or anti-β2GPI. Two patients had low aCL levels and two were negative at the time of acute DVT but later met APS criteria due to lupus anticoagulant (LA). Our data indicate that negative aCL and/or anti-β2GPI at the time of acute DVT make further aPL testing unnecessary; however, LA should be determined after discontinuation of anticoagulant therapy. Positive aCL and/or anti-β2GPI at the time of acute DVT have a strong positive predictive value for APS and may support therapeutic decisions.

show abstract

Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?

Cited by 23 publications

References 51 publications

Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome

Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome

Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS)

The Predictive Value of the aCL and Anti-β2GPI at the Time of Acute Deep Vein Thrombosis—A Two-Year Prospective Study

Contact Info

Product

Resources

About